Abstract
Fifty patients with mild to moderate essential hypertension were randomized to receive either 20 mg fosinopril daily for 16 weeks or placebo for 4 weeks followed by 12 weeks of 50 mg atenolol daily. Prior to these 16 weeks there was a placebo wash-out period of 2–6 weeks. Blood pressure measurements, euglycaemic, hyperinsulinaemic glucose clamps, and intravenous glucose tolerance tests (IVGTT) were performed at baseline and after 4 and 16 weeks. Blood lipid status was evaluated at baseline and 16 weeks.
The insulin sensitivity index (M/I) increased by 12% during the prolonged placebo period, and subsequently decreased by 12% during treatment with atenolol in that group. A post-hoc analysis of covariance indicated that the increase in insulin sensitivity during the initial 4 weeks may have been due to carry over effects from previous anti-hypertensive treatment. Fosinopril increased glucose disappearance during IVGTT at 4 and 16 weeks (k values 1.46 and 1.33 vs 1.10 at baseline) but had no effect on insulin sensitivity. The change in insulin sensitivity and serum triglycerides during treatment with fosinopril was related to angiotensin-converting enzyme inhibition in serum.
In conclusion, carry-over effects from previous anti-hypertensive medication were indicated in this study, probably because of an insufficient wash-out period in many patients. Therefore, 4 weeks of placebo wash-out in all patients is advisable in this kind of investigation.
This is a preview of subscription content, log in via an institution to check access.
Similar content being viewed by others
References
Berne C, Pollare T, Lithell H (1991) Effects of antihypertensive treatment on insulin sensitivity with special reference to ACE inhibitors. Diabetes Care 14: 39–47
Lithell H (1991) Effect of antihypertensive drugs on insulin, glucose, and lipid metabolism. Diabetes Care 14: 203–209
DeFronzo RA, Tobin JD, Andres R (1979) Glucose clamp technique: a method for quantifying insulin secretion and resistance. Am J Physiol 6:E214-E223
Ikkos D, Luft R (1957) On the intravenous tolerance test. Acta Endocrinol 25: 312–334
Friedland J, Silverstein E (1976) A sensitive fluorimetric assay for serum angiotensin-converting enzyme. Am J Clin Pathol 66: 416–24
Pollare T, Lithell H, Berne C (1989) A comparison of the effects of hydrochlorothiazide and captopril on glucose and lipid metabolism in patients with hypertension. N Engl J Med 321: 868–873
Pollare T, Lithell H, Mörlin C, Präntare H, Hvarfner A, Ljunghall S (1989) Metabolic effects of diltiazem and atenolol: results from a randomized, double blind study with parallel groups. J Hypertens 7: 551–559
Pollare T, Lithell H, Selinus I, Berne C (1989) Sensitivity to insulin during treatment with atenolol and metoprolol: a randomized, double-blind study of effects on carbohydrate and lipoprotein metabolism in hypertensive patients. BMJ 298: 1152–1157
Laakso M, Edelman SV, Brechtel G, Baron AD (1990) Decreased effect of insulin to stimulate skeletal muscle blood flow in obese man: a novel mechanism for insulin resistance. J Clin Invest 85: 1844–1853
Baron AD, Brechtel-Hook G, Johnson A, Hardin D (1993) Skeletal muscle blood flow — a possible link between insulin resistance and blood pressure. Hypertension 21: 129–135
Laakso M, Edelman SV, Brechtel G, Baron AD (1992) Impaired insulin-mediated blood flow in patients with NIDDM. Diabetes 41: 1076–1083
Pollare T, Lithell H, Selinus I, Berne C (1988) Application of prazosin is associated with an increase of insulin sensitivity in obese patients with hypertension. Diabetologia 31: 415–420
Andersson P-E, Johansson J, Berne C, Lithell H (1994) Effects of selective alpha-1 and beta-1 adrenoreceptor blockade on lipoprotein and carbohydrate metabolism in hypertensive subjects, with special emphasis on insulin sensitivity. J Hum Hypertens 8: 219–226
Alleman Y, Baumann S, Jost M et al (1992) Insulin sensitivity in normotensive subjects during angiotensin converting enzyme inhibition with fosinopril. Eur J Clin Pharmacol 42: 275–280
Lees KR (1992) The dose-response relationship with angiotensin-converting enzyme inhibitors: effects on blood pressure and biochemical parameters. J Hypertens 10 [Suppl 5]:s3-s11
Santoro D, Natali A, Palombo C et al (1992) Effects of chronic angiotensin converting enzyme inhibition on glucose tolerance and insulin sensivitiy in essential hypertension. Hypertension 20: 181–191
Haenni A, Andersson P-E, Lind L, Berne C, Lithell H (1993) Metabolic effects during lisinopril/bendrofluazide treatment. Results from a randomised, double-blind study with parallel groups. (abstract) Sixth European Meeting on Hypertension, Milan, 4–7 June
Paolisso G, Gambardella A, Verza M, D'Amore A, Sgambato S, Varricchio M (1992) ACE inhibition improves insulin-sensitivity in aged insulin-resistant hypertensive patients. J Hum Hypertens 6: 175–179
Morris AD, Petrie J, Anderson J, Connell JMC, Donnelly R (1993) The effects of pressor and sub-pressor doses of angiotensin II on insulin sensitivity: a placebo-controlled study. (abstract) Sixth European Meeting on Hypertension, Milan, 4–7 June
Widgren BR, Urbanavicus V, Wikstrand J, Attvall S, Persson B (1993) Low dose angiotensin II increases glucose disposal rate during euglycemic hyperinsulinemia. (abstract) Sixth European Meeting on Hypertension, Milan, 4–7 June
Shionoiri H, Miyakawa T, Takasaki I et al (1987) Glucose tolerance during chronic captopril therapy in patients with essential hypertension. J Cardiovasc Pharmacol 9: 160–164
Shionoiri H, Sugimoto K, Minamisawa K et al (1990) Glucose and lipid metabolism during long-term treatment with cilazapril in hypertensive patients with or without impaired glucose metabolism. J Cardiovasc Pharmacol 15: 933–938
Shionoiri H, Ueda S, Gotoh E, Ito T, Ogihara T (1990) Glucose and lipid metabolism during long-term lisinopril therapy in hypertensive patients. J Cardiovasc Pharmacol 16: 905–909
Ludvik B, Kueenburg E, Brunnbauer M, Schernthaner G, Prager R (1991) The effects of ramipril on glucose tolerance, insulin secretion, and insulin sensitivity in patients with hypertension. J Cardiovasc Pharmacol 18:S157-S159
Oksa A, Gajdos M, Fedelesova V, Spustova V, Dzurik R (1994) Effects of angiotensin-converting enzyme inhibitors on glucose and lipid metabolism in essential hypertension. J Cardiovasc Pharmacol23: 79–86
Author information
Authors and Affiliations
Rights and permissions
About this article
Cite this article
Reneland, R., Andersson, PE., Haenni, A. et al. Metabolic effects of long-term angiotensin-converting enzyme inhibition with fosinopril in patients with essential hypertension: relationship to angiotensin-converting enzyme inhibition. Eur J Clin Pharmacol 46, 431–436 (1994). https://doi.org/10.1007/BF00191906
Received:
Accepted:
Issue Date:
DOI: https://doi.org/10.1007/BF00191906